Join
Live feed
·
PRReleasevia Quantisnow
NKGen Biotech Inc. logo

NKGen Biotech Reports Combined Phase 1 Troculeucel Data Demonstrating Dose-Responsive Cognitive Improvements and Biomarker Correlations in Alzheimer's Disease at AD/PD 2026™

ByQuantisnow·Wall Street's wire, on your screen.
NKGN· NKGen Biotech Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track NKGN (NKGen Biotech Inc.) and more on Quantisnow.